Safety
In the eltrombopag group, there were no cases of eltrombopag withdrawal
due to adverse reactions. The most common adverse events were indirect
bilirubin elevation and jaundice (13.6%, 9 patients). Three patients
(4.5%) showed transient elevations of liver enzyme levels. One patient
showed elevated uric acid (1.5%). The above abnormal laboratory
indicators self-resolved or disappeared after eltrombopag withdrawal.
None of the patients developed new cataracts or thromboembolic events
during the study, and no rashes or myelofibrosis were reported. Adverse
events not attributed to eltrombopag by the investigators included
neutropenic infections and known toxic effects of rATG and CSA. One
patient showed femoral head necrosis at 1 year after IST, which improved
after surgery.